IL254520A0 - Heterocyclic tricyclic compounds for use as tnf inhibitors - Google Patents
Heterocyclic tricyclic compounds for use as tnf inhibitorsInfo
- Publication number
- IL254520A0 IL254520A0 IL254520A IL25452017A IL254520A0 IL 254520 A0 IL254520 A0 IL 254520A0 IL 254520 A IL254520 A IL 254520A IL 25452017 A IL25452017 A IL 25452017A IL 254520 A0 IL254520 A0 IL 254520A0
- Authority
- IL
- Israel
- Prior art keywords
- tnf
- inhibitors
- heterocyclic compounds
- compounds useful
- tricyclic heterocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134779P | 2015-03-18 | 2015-03-18 | |
| PCT/US2016/022738 WO2016149437A1 (en) | 2015-03-18 | 2016-03-17 | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL254520A0 true IL254520A0 (en) | 2017-11-30 |
Family
ID=55640933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254520A IL254520A0 (en) | 2015-03-18 | 2017-09-15 | Heterocyclic tricyclic compounds for use as tnf inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10308652B2 (enExample) |
| EP (1) | EP3271361B1 (enExample) |
| JP (1) | JP6793658B2 (enExample) |
| KR (1) | KR102630010B1 (enExample) |
| CN (1) | CN107635992B (enExample) |
| AU (1) | AU2016233289A1 (enExample) |
| BR (1) | BR112017019731A2 (enExample) |
| CA (1) | CA2982446A1 (enExample) |
| EA (1) | EA032314B1 (enExample) |
| ES (1) | ES2797685T3 (enExample) |
| IL (1) | IL254520A0 (enExample) |
| MX (1) | MX2017011433A (enExample) |
| SG (1) | SG11201707471RA (enExample) |
| WO (1) | WO2016149437A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2803650T3 (es) | 2015-03-18 | 2021-01-28 | Bristol Myers Squibb Co | Compuestos heterocíclicos útiles como inhibidores de TNF |
| ES2797805T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos sustituidos |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| UY36630A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| EP3331889B1 (en) | 2015-08-03 | 2020-09-23 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| EP3596078B1 (en) | 2017-03-15 | 2023-04-12 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| ATE238998T1 (de) | 1997-02-25 | 2003-05-15 | Us Gov Health & Human Serv | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore |
| AU7922900A (en) * | 1999-10-27 | 2001-05-08 | Novartis Ag | Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use |
| EP1479681A4 (en) | 2002-01-31 | 2006-05-10 | Daiichi Seiyaku Co | IMIDAZO (1,2-a) pyridine |
| WO2004050035A2 (en) | 2002-12-03 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| WO2009045174A1 (en) | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| CA2874303C (en) | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| US9309243B2 (en) * | 2012-07-13 | 2016-04-12 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| MX2015005375A (es) * | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| ES2529865B8 (es) * | 2013-07-25 | 2016-01-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| EP3080085B1 (en) | 2013-12-09 | 2019-08-14 | UCB Biopharma SPRL | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2015086519A1 (en) | 2013-12-09 | 2015-06-18 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of tnf activity |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| KR20230035424A (ko) | 2014-10-06 | 2023-03-13 | 시그날 파마소티칼 엘엘씨 | 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| ES2797805T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos sustituidos |
| ES2803650T3 (es) | 2015-03-18 | 2021-01-28 | Bristol Myers Squibb Co | Compuestos heterocíclicos útiles como inhibidores de TNF |
| UY36630A (es) * | 2015-04-17 | 2016-11-30 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| EP3292127A1 (en) * | 2015-05-04 | 2018-03-14 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
-
2016
- 2016-03-17 BR BR112017019731-6A patent/BR112017019731A2/pt not_active Application Discontinuation
- 2016-03-17 EA EA201792025A patent/EA032314B1/ru not_active IP Right Cessation
- 2016-03-17 CA CA2982446A patent/CA2982446A1/en not_active Abandoned
- 2016-03-17 WO PCT/US2016/022738 patent/WO2016149437A1/en not_active Ceased
- 2016-03-17 CN CN201680025154.3A patent/CN107635992B/zh active Active
- 2016-03-17 EP EP16712646.5A patent/EP3271361B1/en active Active
- 2016-03-17 SG SG11201707471RA patent/SG11201707471RA/en unknown
- 2016-03-17 ES ES16712646T patent/ES2797685T3/es active Active
- 2016-03-17 JP JP2017549093A patent/JP6793658B2/ja active Active
- 2016-03-17 AU AU2016233289A patent/AU2016233289A1/en not_active Abandoned
- 2016-03-17 KR KR1020177029450A patent/KR102630010B1/ko active Active
- 2016-03-17 MX MX2017011433A patent/MX2017011433A/es unknown
- 2016-03-17 US US15/558,708 patent/US10308652B2/en active Active
-
2017
- 2017-09-15 IL IL254520A patent/IL254520A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6793658B2 (ja) | 2020-12-02 |
| SG11201707471RA (en) | 2017-10-30 |
| EP3271361A1 (en) | 2018-01-24 |
| ES2797685T3 (es) | 2020-12-03 |
| EA032314B1 (ru) | 2019-05-31 |
| JP2018508554A (ja) | 2018-03-29 |
| KR20170129811A (ko) | 2017-11-27 |
| MX2017011433A (es) | 2017-11-10 |
| CA2982446A1 (en) | 2016-09-22 |
| CN107635992A (zh) | 2018-01-26 |
| AU2016233289A1 (en) | 2017-11-09 |
| WO2016149437A1 (en) | 2016-09-22 |
| US20180111937A1 (en) | 2018-04-26 |
| CN107635992B (zh) | 2020-05-22 |
| EA201792025A1 (ru) | 2018-01-31 |
| US10308652B2 (en) | 2019-06-04 |
| KR102630010B1 (ko) | 2024-01-25 |
| EP3271361B1 (en) | 2020-04-22 |
| BR112017019731A2 (pt) | 2018-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| ZA201800716B (en) | Heterocyclic compounds useful as modulators of tnf alpha | |
| ZA201706710B (en) | Heterocyclic compounds as lsd1 inhibitors | |
| SMT202200250T1 (it) | Composti eterociclici come inibitori della pi3k-gamma | |
| IL255817B (en) | Synthesis of heterocyclic compounds | |
| ZA201700304B (en) | Spirocycloheptanes as inhibitors of rock | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| SG11201707471RA (en) | Tricyclic heterocyclic compounds useful as inhibitors of tnf | |
| IL255358B (en) | Naphthyridine compounds as jak kinase inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA201605586B (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| IL254430A0 (en) | Heterocyclic compounds are useful as TNF inhibitors | |
| IL254424A0 (en) | Disubstituted heterocyclic tricyclic compounds | |
| IL257501B (en) | Compounds containing heterocyclic tricyclic compounds |